TCGA-A2-A0YM-01A-11R-A109-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 32
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.560
- MITOTIC_SPINDLE+0.480
- MYC_TARGETS_V2+0.470
- INFLAMMATORY_RESPONSE+0.410
- INTERFERON_ALPHA_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.390
- TNFA_SIGNALING_VIA_NFKB+0.380
- IL6_JAK_STAT3_SIGNALING+0.370
- MYC_TARGETS_V1+0.370
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.480
- BILE_ACID_METABOLISM-0.360
- ADIPOGENESIS-0.330
- ESTROGEN_RESPONSE_EARLY-0.330
- FATTY_ACID_METABOLISM-0.300
- PEROXISOME-0.280
- XENOBIOTIC_METABOLISM-0.220
- APICAL_SURFACE-0.180
- ESTROGEN_RESPONSE_LATE-0.170
- PANCREAS_BETA_CELLS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-S3-AA10-01A-21R-A41B-07 | — | E | 0.873 |
| 2 | TCGA-A2-A0CM-01A-31R-A034-07 | — | E | 0.845 |
| 3 | TCGA-BH-A18V-01A-11R-A12D-07 | — | E | 0.837 |
| 4 | TCGA-E2-A1AZ-01A-11R-A12P-07 | — | D | 0.833 |
| 5 | TCGA-C8-A27B-01A-11R-A169-07 | — | E | 0.832 |
| 6 | SRR29022833 | — | D | 0.831 |
| 7 | TCGA-55-A493-01A-11R-A24H-07 | — | cohortA1 | 0.824 |
| 8 | TCGA-A2-A0SX-01A-12R-A084-07 | — | D | 0.823 |
| 9 | TCGA-AO-A0J4-01A-11R-A034-07 | — | E | 0.823 |
| 10 | 20040077.TNBC | — | E | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |